New aptamer-based drugs for wound healing and inflammatory diseases

CIEMAT, the Carlos III University of Madrid, the Foundation for Biomedical Research of the Ramón y Cajal University Hospital, Aptus Biotech, S.L. and the Health Research Institute Foundation of the Fundación Jiménez Díaz have developed a new targeted therapy based on DNA aptamers for wound healing, with the aim of improving efficacy and avoiding degradation in the proteolytic environment of chronic wounds. These aptamers have been generated against a receptor (FPR2) involved in the control of inflammation, so they have a great therapeutic potential against multiple inflammatory diseases.